UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. _______)*
Meridian Medical Technologies, Inc.
(formerly Survival Technology, Inc.)
- -------------------------------------------------------------------------------
(Name of Issuer)
- -------------------------------------------------------------------------------
Common Stock, .10 par value
(Title of Class of Securities)
869028100
(CUSIP Number)
Patricia Sunseri
Mylan Laboratories, Inc.
130 Seventh Street, 1030 Century Bldg.
Pittsburgh, PA 15222
(412) 232-0100
_______________________________________________________________________________
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
November 20, 1996
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report to acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [].
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
SCHEDULE 13D
CUSIP No.869028100 Page 2 of 6 Pages
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mylan Laboratories, Inc.
25-1211621
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) []
(b) []
3 SEC USE ONLY
4 SOURCE OF FUNDS*
OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []
6 CITIZENSHIP OR PLACE OR ORGANIZATION
Pennsylvania
7 SOLE VOTING POWER
NUMBER OF 272,299
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
8 SHARED VOTING POWER
None
9 SOLE DISPOSITIVE POWER
272,299
10 SHARED DISPOSITIVE POWER
None
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
272,299
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* []
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.2%
14 TYPE OF REPORTING PERSON*
CO
===============================================================================
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
Item 1. Security and Issuer. Page 3 of 6 Pages
This Statement on Schedule 13D (the "Schedule 13D") relates to the Common
Stock, par value $.01 per share (the "Common Stock), of Meridian Medical
Technologies, Inc, a Delaware corporation (formerly Survival Technology, Inc.)
(the "Issuer"). The Issuer's principal executive offices are located at 2275
Research Boulevard, Rockville, MD 20850.
Item 2. Identify and Background.
This Schedule 13D is filed on behalf of Mylan Laboratories, Inc. a
Pennsylvania corporation (the "Reporting Person"). The Reporting Person is
primarily engaged in the development, manufacturing and distribution of
pharmaceutical products for resale by others. The principal place of business
and executive offices of the Reporting Person are located at 130 Seventh Street,
1030 Century Building, Pittsburgh, PA 15222.
Filed as Schedule I to this Schedule 13D is a list of the executive
officers and directors of the Reporting Person containing the following
information with respect to such persons: (i) name, (ii) business address and
(iii) present principal occupation or employment and the name and, if different
from the person's business address, the address of any other corporation or
organization in which such employment is conducted. Each person listed in
Schedule I is a United States citizen.
During the past five years, neither the Reporting Person nor any person
named in Schedule I (based on information provided by such individuals) has been
(i) involved in a criminal proceeding or (ii) a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
This Schedule 13D relates to the beneficial ownership of the Reporting
Person of 272,299 shares of Common Stock of the Issuer. Of such 272,299 shares
of Common Stock, 43,556 are issuable on exercise of currently exercisable
warrants to purchase shares of Common Stock. On April 15, 1996, the Reporting
Person acquired 108,892 shares of Series F 10% Convertible Preferred Stock, $
.01 par value (the "Preferred Stock") of Brunswick Biomedical Corporation
("Brunswick"). In connection with the merger of Brunswick into the Issuer, which
transaction was consummated on or about November 20, 1996, each share of the
Preferred Stock was converted into 2.1 shares of Common Stock and a warrant to
purchase 0.4 shares of Common Stock as $11.00 per share exercisable for five
years from the effective time of the merger.
Item 4. Purpose of Transaction.
The Reporting Person has acquired the Common Stock and the Warrants for
investment purposes. The Reporting Person reserves the right to acquire
additional Common Stock or to dispose of some or all of the Common Stock
beneficially owned by it either in the open market, in privately negotiated
transactions or otherwise, or take such other action or actions with respect to
the Common Stock as it deems advisable to the extent permitted under applicable
federal and state securities law; however, the Reporting Person has no present
intention of engaging in any such transaction.
Except as set forth above, the Reporting Person has no plans or proposals
which relate to or would result in any of the following:
(a) The acquisition by any person of additional securities of the Issuer, or
the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction, such as a merger, reorganization or
liquidation, involving the Issuer;
(c) A sale or transfer of a material amount of assets of the Issuer;
<PAGE>
Page 4 of 6 Pages
(d) Any change in the present board of directors or management of the Issuer,
including any plans or proposals to change the number or term of directors
or to fill any existing vacancies on the board;
(e) Any material change in the present capitalization or dividend policy of the
Issuer;
(f) Any other material change in the Issuer's business or corporate structure;
(g) Changes in the Issuer's articles of incorporation or bylaws or other
actions which may impede the acquisition of control of the Issuer by any
person;
(h) Causing a class of securities of the Issuer to be delisted from a national
securities exchange or to cease to be authorized to be quoted in an
inter-dealer quotation system of a registered national securities
association;
(i) A class of equity of the Issuer becoming eligible for termination of
registration pursuant to Section 12(g)(4) of the 1934 Act; or
(j) Any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer.
The number of shares of Common Stock issued and outstanding and the
percentage calculation resulting therefrom in this Schedule 13-D are based on
information contained in the definitive proxy statement of the Issuer dated
October 30, 1996. The Reporting Person disclaims responsibility for the accuracy
of the number of shares of Common Stock issued and outstanding and the resulting
percentage calculations.
The Reporting Person beneficially owns 272,299 shares of Common Stock,
representing approximately 9.2% of the Common Stock issued and outstanding;
43,556 of such shares are issuable on exercise of currently exercisable
warrants. The Reporting Person has sole voting and disposition power with
respect to all Common Stock beneficially owned by it. None of the persons listed
on Schedule I owns Common Stock.
Except as described herein, no transactions in Common Stock were effected
during the past 60 days by the Reporting Person.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
Not applicable.
Item 7. Materials to be Filed as Exhibits.
None
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: November 27, 1996 MYLAN LABORATORIES, INC.
___________________________________
By:
Title:
<PAGE>
Page 5 of 6 pages SCHEDULE I
The following is a list of the executive officers and directors of the
Reporting Person. Unless otherwise indicated, the business address of each
executive officer and director is 130 Seventh Street, 1030 Century Bldg.,
Pittsburgh, PA 15222.
Executive Officers
--------------------------------
Name Office Held (Principal Occupation)
- ------------- ---------------------------------------
Milan Puskar Chairman, CEO & President
Dana G. Barnett Executive Vice President
Louis J. DeBone Vice President - Operations
Roger L. Foster Vice President & General Counsel
Roderick P. Jackson Senior Vice President
Joseph J. Krivulka Vice President
Dr. John P. O'Donnell Vice President - Research & Quality Control
Robert W. Smiley, Esquire Secretary
Doepken Keevican & Weiss,
Professional Corporation.
600 Grant Street, USX Tower
37 Floor
Pittsburgh, PA 15219
Patricia Sunseri Vice President - Investor and Public Relations
C.B. Todd Senior Vice President
Directors
Name and Principal Occupation Business Address
- --------------------------------- -----------------------------
Milan Puskar Chairman of the Board, CEO &
President of Mylan Laboratories, Inc.
C.B. Todd President of Mylan Pharmaceuticals, Inc.
Dana G. Barnett Executive Vice President of Mylan
Laboratories, Inc.
Laurence S. DeLyn Retail Consultant
John C. Gaisford, M.D. Director of Burn Research West Penn Hospital
West Penn Hospital
Suite 340 Mellon Pavillion
Pittsburgh, PA 15224
<PAGE> Page 6 of 6 pages
Robert W. Smiley, Esquire Doepken, Keevican & Weiss, .
Professional Corporation
600 Grant Street, USX Tower
37th Floor
Pittsburgh, PA 15219
